<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33925625</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>27</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>iPSCs: A Preclinical Drug Research Tool for Neurological Disorders.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4596</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22094596</ELocationID><Abstract><AbstractText>The development and commercialization of new drugs is an articulated, lengthy, and very expensive process that proceeds through several steps, starting from target identification, screening new leading compounds for testing in preclinical studies, and subsequently in clinical trials to reach the final approval for therapeutic use. Preclinical studies are usually performed using both cell cultures and animal models, although they do not completely resume the complexity of human diseases, in particular neurodegenerative conditions. To this regard, stem cells represent a powerful tool in all steps of drug discovery. The recent advancement in induced Pluripotent Stem Cells (iPSCs) technology has opened the possibility to obtain patient-specific disease models for drug screening and development. Here, we report the use of iPSCs as a disease model for drug development in the contest of neurological disorders, including Alzheimer's (AD) and Parkinson's disease (PD), Amyotrophic lateral Sclerosis (ALS), and Fragile X syndrome (FRAX).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonaventura</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute for Biomedical Research and Innovation (IRIB), Italian National Research Council, 95126 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iemmolo</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-9297-8115</Identifier><AffiliationInfo><Affiliation>Institute for Biomedical Research and Innovation (IRIB), Italian National Research Council, 95126 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attaguile</LastName><ForeName>Giuseppe Antonino</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Biotechnological Sciences (BIOMETEC), Section of Pharmacology, University of Catania, 95123 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Cognata</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute for Biomedical Research and Innovation (IRIB), Italian National Research Council, 95126 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pistone</LastName><ForeName>Brigida Sabrina</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Institute for Biomedical Research and Innovation (IRIB), Italian National Research Council, 95126 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raudino</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Ortho-Neuro Center HUMANITAS Istituto Clinico Catanese, 95045 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Agata</LastName><ForeName>Velia</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-1114-8265</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Biotechnological Sciences, Section of Anatomy, Histology and Movement Sciences, University of Catania, 95123 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantarella</LastName><ForeName>Giuseppina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Biotechnological Sciences (BIOMETEC), Section of Pharmacology, University of Catania, 95123 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barcellona</LastName><ForeName>Maria Luisa</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Science, Biochemistry Section, University of Catania, 95123 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavallaro</LastName><ForeName>Sebastiano</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7590-1792</Identifier><AffiliationInfo><Affiliation>Institute for Biomedical Research and Innovation (IRIB), Italian National Research Council, 95126 Catania, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CIP 2014.IT.05.SFOP.014/3/10.4/9.2.10/0008</GrantID><Agency>European Social Fund</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AD</Keyword><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">FRAX</Keyword><Keyword MajorTopicYN="N">PD</Keyword><Keyword MajorTopicYN="N">drug development</Keyword><Keyword MajorTopicYN="N">iPSCs</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>30</Day><Hour>1</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33925625</ArticleId><ArticleId IdType="pmc">PMC8123805</ArticleId><ArticleId IdType="doi">10.3390/ijms22094596</ArticleId><ArticleId IdType="pii">ijms22094596</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mager D.E., Woo S., Jusko W.J. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab. Pharmacokinet. 2009;24:16&#x2013;24. doi: 10.2133/dmpk.24.16.</Citation><ArticleIdList><ArticleId IdType="doi">10.2133/dmpk.24.16</ArticleId><ArticleId IdType="pmc">PMC3727168</ArticleId><ArticleId IdType="pubmed">19252333</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang R., Li D., Tang I.-C., Wang J., Yang S.-T. Cell-based assays in high-throughput screening for drug discovery. Int. J. Biotechnol. Wellness Ind. 2012;1:31&#x2013;51.</Citation></Reference><Reference><Citation>Ransohoff R.M. All (animal) models (of neurodegeneration) are wrong. Are they also useful? J. Exp. Med. 2018;215:2955&#x2013;2958. doi: 10.1084/jem.20182042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20182042</ArticleId><ArticleId IdType="pmc">PMC6279414</ArticleId><ArticleId IdType="pubmed">30459159</ArticleId></ArticleIdList></Reference><Reference><Citation>Elitt M.S., Barbar L., Tesar P.J. Drug screening for human genetic diseases using iPSC models. Hum. Mol. Genet. 2018;27:R89&#x2013;R98. doi: 10.1093/hmg/ddy186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy186</ArticleId><ArticleId IdType="pmc">PMC6061782</ArticleId><ArticleId IdType="pubmed">29771306</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663&#x2013;676. doi: 10.1016/j.cell.2006.07.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.07.024</ArticleId><ArticleId IdType="pubmed">16904174</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861&#x2013;872. doi: 10.1016/j.cell.2007.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.11.019</ArticleId><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Seki T., Fukuda K. Methods of induced pluripotent stem cells for clinical application. World J. Stem Cells. 2015;7:116&#x2013;125. doi: 10.4252/wjsc.v7.i1.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.4252/wjsc.v7.i1.116</ArticleId><ArticleId IdType="pmc">PMC4300922</ArticleId><ArticleId IdType="pubmed">25621111</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G., David B.T., Trawczynski M., Fessler R.G. Advances in pluripotent stem cells: History, mechanisms, technologies, and applications. Stem Cell Rev. Rep. 2020;16:3&#x2013;32. doi: 10.1007/s12015-019-09935-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-019-09935-x</ArticleId><ArticleId IdType="pmc">PMC6987053</ArticleId><ArticleId IdType="pubmed">31760627</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y. Global prevalence of dementia: A Delphi consensus study. Lancet. 2005;366:2112&#x2013;2117. doi: 10.1016/S0140-6736(05)67889-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)67889-0</ArticleId><ArticleId IdType="pmc">PMC2850264</ArticleId><ArticleId IdType="pubmed">16360788</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman B.T., Van Hoesen G.W., Damasio A.R., Barnes C.L. Alzheimer&#x2019;s disease: Cell-specific pathology isolates the hippocampal formation. Science. 1984;225:1168&#x2013;1170. doi: 10.1126/science.6474172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.6474172</ArticleId><ArticleId IdType="pubmed">6474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi R.E. The genetics of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012;2:a006296. doi: 10.1101/cshperspect.a006296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006296</ArticleId><ArticleId IdType="pmc">PMC3475404</ArticleId><ArticleId IdType="pubmed">23028126</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanoisel&#xe9;e H.-M., Nicolas G., Wallon D., Rovelet-Lecrux A., Lacour M., Rousseau S., Richard A.-C., Pasquier F., Rollin-Sillaire A., Martinaud O. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med. 2017;14:e1002270. doi: 10.1371/journal.pmed.1002270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002270</ArticleId><ArticleId IdType="pmc">PMC5370101</ArticleId><ArticleId IdType="pubmed">28350801</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekris L.M., Yu C.-E., Bird T.D., Tsuang D.W. Genetics of Alzheimer disease. J. Geriatr. Psychiatry Neurol. 2010;23:213&#x2013;227. doi: 10.1177/0891988710383571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0891988710383571</ArticleId><ArticleId IdType="pmc">PMC3044597</ArticleId><ArticleId IdType="pubmed">21045163</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh K., Abe-Dohmae S., Yokoyama S., St George-Hyslop P., Fraser P.E. ATP-binding cassette transporter A7 (ABCA7) loss of function alters Alzheimer amyloid processing. J. Biol. Chem. 2015;290:24152&#x2013;24165. doi: 10.1074/jbc.M115.655076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.655076</ArticleId><ArticleId IdType="pmc">PMC4591804</ArticleId><ArticleId IdType="pubmed">26260791</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettens K., Vermeulen S., Van Cauwenberghe C., Heeman B., Asselbergh B., Robberecht C., Engelborghs S., Vandenbulcke M., Vandenberghe R., De Deyn P.P. Reduced secreted clusterin as a mechanism for Alzheimer-associated CLU mutations. Mol. Neurodegener. 2015;10:1&#x2013;12. doi: 10.1186/s13024-015-0024-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0024-9</ArticleId><ArticleId IdType="pmc">PMC4502563</ArticleId><ArticleId IdType="pubmed">26179372</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J.-C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat. Genet. 2009;41:1094&#x2013;1099. doi: 10.1038/ng.439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.439</ArticleId><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardarajan B.N., Ghani M., Kahn A., Sheikh S., Sato C., Barral S., Lee J.H., Cheng R., Reitz C., Lantigua R. Rare coding mutations identified by sequencing of A lzheimer disease genome-wide association studies loci. Ann. Neurol. 2015;78:487&#x2013;498. doi: 10.1002/ana.24466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24466</ArticleId><ArticleId IdType="pmc">PMC4546546</ArticleId><ArticleId IdType="pubmed">26101835</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel D., Mez J., Vardarajan B.N., Staley L., Chung J., Zhang X., Farrell J.J., Rynkiewicz M.J., Cannon-Albright L.A., Teerlink C.C. Association of rare coding mutations with Alzheimer disease and other dementias among adults of European ancestry. JAMA Netw. Open. 2019;2:e191350. doi: 10.1001/jamanetworkopen.2019.1350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2019.1350</ArticleId><ArticleId IdType="pmc">PMC6450321</ArticleId><ArticleId IdType="pubmed">30924900</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuccaro M.L., Carney R.M., Zhang Y., Bohm C., Kunkle B.W., Vardarajan B.N., Whitehead P.L., Cukier H.N., Mayeux R., George-Hyslop P.S. SORL1 mutations in early-and late-onset Alzheimer disease. Neurol. Genet. 2016;2:e116. doi: 10.1212/NXG.0000000000000116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000116</ArticleId><ArticleId IdType="pmc">PMC5082932</ArticleId><ArticleId IdType="pubmed">27822510</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey C.C., DeVaux L.B., Farzan M. The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E. J. Biol. Chem. 2015;290:26033&#x2013;26042. doi: 10.1074/jbc.M115.677286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.677286</ArticleId><ArticleId IdType="pmc">PMC4646256</ArticleId><ArticleId IdType="pubmed">26374897</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellenguez C., Grenier-Boley B., Lambert J.-C. Genetics of Alzheimer&#x2019;s disease: Where we are, and where we are going. Curr. Opin. Neurobiol. 2020;61:40&#x2013;48. doi: 10.1016/j.conb.2019.11.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2019.11.024</ArticleId><ArticleId IdType="pubmed">31863938</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashford J.W. APOE genotype effects on Alzheimer&#x2019;s disease onset and epidemiology. J. Mol. Neurosci. 2004;23:157&#x2013;165. doi: 10.1385/JMN:23:3:157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/JMN:23:3:157</ArticleId><ArticleId IdType="pubmed">15181244</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Rimmler J.B., Locke P.A., Conneally P.M., Schmader K.E., et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 1994;7:180&#x2013;184. doi: 10.1038/ng0694-180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0694-180</ArticleId><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Cusulin C., Wells I., Badillo S., Duran-Pacheco G.C., Baumann K., Patsch C. Gamma secretase modulators and BACE inhibitors reduce A&#x3b2; production without altering gene expression in Alzheimer&#x2019;s disease iPSC-derived neurons and mice. Mol. Cell. Neurosci. 2019;100:103392. doi: 10.1016/j.mcn.2019.103392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2019.103392</ArticleId><ArticleId IdType="pubmed">31381983</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang K.-H., Lee-Chen G.-J., Huang C.-C., Lin J.-L., Chen Y.-J., Wei P.-C., Lo Y.-S., Yao C.-F., Kuo M.-W., Chen C.-M. Modeling Alzheimer&#x2019;s disease by induced pluripotent stem cells carrying APP D678H mutation. Mol. Neurobiol. 2019;56:3972&#x2013;3983. doi: 10.1007/s12035-018-1336-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1336-x</ArticleId><ArticleId IdType="pmc">PMC6505505</ArticleId><ArticleId IdType="pubmed">30238389</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Leon J.A., Caceres-Palomo L., Sanchez-Mejias E., Mejias-Ortega M., Nu&#xf1;ez-Diaz C., Fernandez-Valenzuela J.J., Sanchez-Varo R., Davila J.C., Vitorica J., Gutierrez A. Human Pluripotent Stem Cell-Derived Neural Cells as a Relevant Platform for Drug Screening in Alzheimer&#x2019;s Disease. Int. J. Mol. Sci. 2020;21:6867. doi: 10.3390/ijms21186867.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21186867</ArticleId><ArticleId IdType="pmc">PMC7558359</ArticleId><ArticleId IdType="pubmed">32962164</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.-E., Shin N., Kook M.G., Kong D., Kim N.G., Choi S.W., Kang K.-S. Human iNSC-derived brain organoid model of lysosomal storage disorder in Niemann&#x2013;Pick disease type C. Cell Death Dis. 2020;11:1&#x2013;13. doi: 10.1038/s41419-020-03262-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-03262-7</ArticleId><ArticleId IdType="pmc">PMC7733597</ArticleId><ArticleId IdType="pubmed">33311479</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi H., Kim H.J., Yang J., Chae S., Lee W., Chung S., Kim J., Choi H., Song H., Lee C.K. Acetylation changes tau interactome to degrade tau in Alzheimer&#x2019;s disease animal and organoid models. Aging Cell. 2020;19:e13081. doi: 10.1111/acel.13081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13081</ArticleId><ArticleId IdType="pmc">PMC6974726</ArticleId><ArticleId IdType="pubmed">31763743</ArticleId></ArticleIdList></Reference><Reference><Citation>Couratier P., Corcia P., Lautrette G., Nicol M., Preux P.-M., Marin B. Epidemiology of amyotrophic lateral sclerosis: A review of literature. Rev. Neurol. 2016;172:37&#x2013;45. doi: 10.1016/j.neurol.2015.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2015.11.002</ArticleId><ArticleId IdType="pubmed">26727307</ArticleId></ArticleIdList></Reference><Reference><Citation>Traxinger K., Kelly C., Johnson B.A., Lyles R.H., Glass J.D. Prognosis and epidemiology of amyotrophic lateral sclerosis: Analysis of a clinic population, 1997&#x2013;2011. Neurol. Clin. Pract. 2013;3:313&#x2013;320. doi: 10.1212/CPJ.0b013e3182a1b8ab.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0b013e3182a1b8ab</ArticleId><ArticleId IdType="pmc">PMC3787117</ArticleId><ArticleId IdType="pubmed">24195020</ArticleId></ArticleIdList></Reference><Reference><Citation>Gros-Louis F., Gaspar C., Rouleau G.A. Genetics of familial and sporadic amyotrophic lateral sclerosis. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2006;1762:956&#x2013;972. doi: 10.1016/j.bbadis.2006.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.01.004</ArticleId><ArticleId IdType="pubmed">16503123</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Cruz S., Cleveland D.W. Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. Curr. Opin. Neurobiol. 2011;21:904&#x2013;919. doi: 10.1016/j.conb.2011.05.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2011.05.029</ArticleId><ArticleId IdType="pmc">PMC3228892</ArticleId><ArticleId IdType="pubmed">21813273</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS genetics, mechanisms, and therapeutics: Where are we now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L., Zhang T., Lu K., Qi S. The progress in C9orf72 research: ALS/FTD pathogenesis, functions and structure. Small Gtpases. 2021:1&#x2013;21. doi: 10.1080/21541248.2021.1892443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21541248.2021.1892443</ArticleId><ArticleId IdType="pubmed">33663328</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan K. Familial amyotrophic lateral sclerosis. Neurol. Clin. 2015;33:807&#x2013;830. doi: 10.1016/j.ncl.2015.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.001</ArticleId><ArticleId IdType="pmc">PMC4670044</ArticleId><ArticleId IdType="pubmed">26515623</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin S., Al Khleifat A., Al-Chalabi A. What causes amyotrophic lateral sclerosis? F1000Research. 2017;6:371. doi: 10.12688/f1000research.10476.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.10476.1</ArticleId><ArticleId IdType="pmc">PMC5373425</ArticleId><ArticleId IdType="pubmed">28408982</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M.K. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. 2019;39:733&#x2013;748. doi: 10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Naujock M., Fumagalli L., Vandoorne T., Baatsen P., Boon R., Ordov&#xe1;s L., Patel A., Welters M., Vanwelden T. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat. Commun. 2017;8:1&#x2013;15. doi: 10.1038/s41467-017-00911-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00911-y</ArticleId><ArticleId IdType="pmc">PMC5636840</ArticleId><ArticleId IdType="pubmed">29021520</ArticleId></ArticleIdList></Reference><Reference><Citation>Okano H., Yasuda D., Fujimori K., Morimoto S., Takahashi S. Ropinirole, a New ALS Drug Candidate Developed Using iPSCs. Trends Pharmacol. Sci. 2020;41:99&#x2013;109. doi: 10.1016/j.tips.2019.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2019.12.002</ArticleId><ArticleId IdType="pubmed">31926602</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi S., Morimoto S., Fukushima K., Nakahara J., Okano H. [Ropinirole Hydrochloride for ALS] Brain Nerve Shinkei Kenkyu No Shinpo. 2019;71:1279&#x2013;1288. doi: 10.11477/mf.1416201438.</Citation><ArticleIdList><ArticleId IdType="doi">10.11477/mf.1416201438</ArticleId><ArticleId IdType="pubmed">31722314</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeish J., Gardner J.P., Wainger B.J., Woolf C.J., Eggan K. From dish to bedside: Lessons learned while translating findings from a stem cell model of disease to a clinical trial. Cell Stem Cell. 2015;17:8&#x2013;10. doi: 10.1016/j.stem.2015.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2015.06.013</ArticleId><ArticleId IdType="pubmed">26140603</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortu&#xf1;o-Costela M.d.C., Cerrada V., Garc&#xed;a-L&#xf3;pez M., Gallardo M.E. The challenge of bringing iPSCs to the patient. Int. J. Mol. Sci. 2019;20:6305. doi: 10.3390/ijms20246305.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20246305</ArticleId><ArticleId IdType="pmc">PMC6940848</ArticleId><ArticleId IdType="pubmed">31847153</ArticleId></ArticleIdList></Reference><Reference><Citation>Pernia C., Tobe B.T., O&#x2019;Donnell R., Snyder E.Y. The evolution of stem cells, disease modeling, and drug discovery for neurological disorders. Stem Cells Dev. 2020;29:1131&#x2013;1141. doi: 10.1089/scd.2019.0217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/scd.2019.0217</ArticleId><ArticleId IdType="pmc">PMC7469697</ArticleId><ArticleId IdType="pubmed">32024446</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger B.J., Macklin E.A., Vucic S., McIlduff C.E., Paganoni S., Maragakis N.J., Bedlack R., Goyal N.A., Rutkove S.B., Lange D.J., et al. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2021;78:186&#x2013;196. doi: 10.1001/jamaneurol.2020.4300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.4300</ArticleId><ArticleId IdType="pmc">PMC7684515</ArticleId><ArticleId IdType="pubmed">33226425</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronica E., Baas F., Iyer A., ten Asbroek A.L., Morello G., Cavallaro S. Molecular classification of amyotrophic lateral sclerosis by unsupervised clustering of gene expression in motor cortex. Neurobiol. Dis. 2015;74:359&#x2013;376. doi: 10.1016/j.nbd.2014.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.12.002</ArticleId><ArticleId IdType="pubmed">25500340</ArticleId></ArticleIdList></Reference><Reference><Citation>Polanco M.J., Pennuto M. Pituitary adenylyl cyclase activating polypeptide (PACAP) signaling and the cell cycle machinery in neurodegenerative diseases. Curr. Pharm. Des. 2018;24:3878&#x2013;3891. doi: 10.2174/1381612825666181127102311.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612825666181127102311</ArticleId><ArticleId IdType="pubmed">30479210</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejda A., Jolivel V., Bourgault S., Seaborn T., Fournier A., Vaudry H., Vaudry D. Inhibitory Effect of PACAP on Caspase Activity in Neuronal Apoptosis: A Better Understanding Towards Therapeutic Applications in Neurodegenerative Diseases. J. Mol. Neurosci. 2008;36:26&#x2013;37. doi: 10.1007/s12031-008-9087-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-008-9087-1</ArticleId><ArticleId IdType="pubmed">18506634</ArticleId></ArticleIdList></Reference><Reference><Citation>Maugeri G., D&#x2019;Amico A.G., Ras&#xe0; D.M., Federico C., Saccone S., Morello G., La Cognata V., Cavallaro S., D&#x2019;Agata V. Molecular mechanisms involved in the protective effect of pituitary adenylate cyclase-activating polypeptide in an in vitro model of amyotrophic lateral sclerosis. J. Cell. Physiol. 2019;234:5203&#x2013;5214. doi: 10.1002/jcp.27328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27328</ArticleId><ArticleId IdType="pubmed">30238989</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang R., Jiang X., Ji R., Meng L., Liu F., Chen X., Xin Y. Therapeutic potential of PACAP for neurodegenerative diseases. Cell. Mol. Biol. Lett. 2015;20:265&#x2013;278. doi: 10.1515/cmble-2015-0008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cmble-2015-0008</ArticleId><ArticleId IdType="pubmed">26204407</ArticleId></ArticleIdList></Reference><Reference><Citation>Reglodi D., Kiss P., Lubics A., Tamas A. Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. Curr. Pharm. Des. 2011;17:962&#x2013;972. doi: 10.2174/138161211795589355.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161211795589355</ArticleId><ArticleId IdType="pubmed">21524257</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello G., Spampinato A.G., Conforti F.L., D&#x2019;Agata V., Cavallaro S. Selection and prioritization of candidate drug targets for amyotrophic lateral sclerosis through a meta-analysis approach. J. Mol. Neurosci. 2017;61:563&#x2013;580. doi: 10.1007/s12031-017-0898-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-017-0898-9</ArticleId><ArticleId IdType="pmc">PMC5359376</ArticleId><ArticleId IdType="pubmed">28236105</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura G., Iemmolo R., D&#x2019;Amico A.G., La Cognata V., Costanzo E., Zappia M., D&#x2019;Agata V., Conforti F.L., Aronica E., Cavallaro S. PACAP and PAC1R are differentially expressed in motor cortex of amyotrophic lateral sclerosis patients and support survival of iPSC-derived motor neurons. J. Cell. Physiol. 2018;233:3343&#x2013;3351. doi: 10.1002/jcp.26182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.26182</ArticleId><ArticleId IdType="pubmed">28926110</ArticleId></ArticleIdList></Reference><Reference><Citation>Osaki T., Uzel S.G., Kamm R.D. Microphysiological 3D model of amyotrophic lateral sclerosis (ALS) from human iPS-derived muscle cells and optogenetic motor neurons. Sci. Adv. 2018;4:eaat5847. doi: 10.1126/sciadv.aat5847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aat5847</ArticleId><ArticleId IdType="pmc">PMC6179377</ArticleId><ArticleId IdType="pubmed">30324134</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Y., Kim J., Park H., Choi H., Kim J. Modelling neurodegenerative diseases with 3D brain organoids. Biol. Rev. 2020;95:1497&#x2013;1509. doi: 10.1111/brv.12626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/brv.12626</ArticleId><ArticleId IdType="pubmed">32568450</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin M.K., Farrer M.J. Genetics and genomics of Parkinson&#x2019;s disease. Genome Med. 2014;6:48. doi: 10.1186/gm566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gm566</ArticleId><ArticleId IdType="pmc">PMC4085542</ArticleId><ArticleId IdType="pubmed">25061481</ArticleId></ArticleIdList></Reference><Reference><Citation>La Cognata V., Morello G., D&#x2019;Agata V., Cavallaro S. Copy number variability in Parkinson&#x2019;s disease: Assembling the puzzle through a systems biology approach. Hum. Genet. 2017;136:13&#x2013;37. doi: 10.1007/s00439-016-1749-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00439-016-1749-4</ArticleId><ArticleId IdType="pmc">PMC5214768</ArticleId><ArticleId IdType="pubmed">27896429</ArticleId></ArticleIdList></Reference><Reference><Citation>La Cognata V., D&#x2019;Agata V., Cavalcanti F., Cavallaro S. Splicing: Is there an alternative contribution to Parkinson&#x2019;s disease? Neurogenetics. 2015;16:245&#x2013;263. doi: 10.1007/s10048-015-0449-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-015-0449-x</ArticleId><ArticleId IdType="pmc">PMC4573652</ArticleId><ArticleId IdType="pubmed">25980689</ArticleId></ArticleIdList></Reference><Reference><Citation>Aflaki E., Borger D.K., Moaven N., Stubblefield B.K., Rogers S.A., Patnaik S., Schoenen F.J., Westbroek W., Zheng W., Sullivan P. A new glucocerebrosidase chaperone reduces &#x3b1;-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and parkinsonism. J. Neurosci. 2016;36:7441&#x2013;7452. doi: 10.1523/JNEUROSCI.0636-16.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0636-16.2016</ArticleId><ArticleId IdType="pmc">PMC4945664</ArticleId><ArticleId IdType="pubmed">27413154</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzulli J.R., Zunke F., Tsunemi T., Toker N.J., Jeon S., Burbulla L.F., Patnaik S., Sidransky E., Marugan J.J., Sue C.M. Activation of &#x3b2;-glucocerebrosidase reduces pathological &#x3b1;-synuclein and restores lysosomal function in Parkinson&#x2019;s patient midbrain neurons. J. Neurosci. 2016;36:7693&#x2013;7706. doi: 10.1523/JNEUROSCI.0628-16.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0628-16.2016</ArticleId><ArticleId IdType="pmc">PMC4951575</ArticleId><ArticleId IdType="pubmed">27445146</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J., Jeon S., Jiang W., Burbulla L.F., Ysselstein D., Oevel K., Krainc D., Silverman R.B. Conversion of Quinazoline Modulators from Inhibitors to Activators of &#x3b2;-Glucocerebrosidase. J. Med. Chem. 2019;62:1218&#x2013;1230. doi: 10.1021/acs.jmedchem.8b01294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.8b01294</ArticleId><ArticleId IdType="pmc">PMC6467782</ArticleId><ArticleId IdType="pubmed">30645117</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M.J., Jeon S., Burbulla L.F., Krainc D. Acid ceramidase inhibition ameliorates &#x3b1;-synuclein accumulation upon loss of GBA1 function. Hum. Mol. Genet. 2018;27:1972&#x2013;1988. doi: 10.1093/hmg/ddy105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy105</ArticleId><ArticleId IdType="pmc">PMC6251682</ArticleId><ArticleId IdType="pubmed">29579237</ArticleId></ArticleIdList></Reference><Reference><Citation>Burbulla L.F., Jeon S., Zheng J., Song P., Silverman R.B., Krainc D. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson&#x2019;s disease. Sci. Transl. Med. 2019;11:eaau6870. doi: 10.1126/scitranslmed.aau6870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau6870</ArticleId><ArticleId IdType="pmc">PMC7359409</ArticleId><ArticleId IdType="pubmed">31619543</ArticleId></ArticleIdList></Reference><Reference><Citation>Burbulla L.F., Song P., Mazzulli J.R., Zampese E., Wong Y.C., Jeon S., Santos D.P., Blanz J., Obermaier C.D., Strojny C. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson&#x2019;s disease. Science. 2017;357:1255&#x2013;1261. doi: 10.1126/science.aam9080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aam9080</ArticleId><ArticleId IdType="pmc">PMC6021018</ArticleId><ArticleId IdType="pubmed">28882997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambasudhan R., Ryan S.D., Dolatabadi N., Chan S.F., Zhang X., Akhtar M.W., Parker J., Soldner F., Sunico C.R., Nagar S. Isogenic Human iPSC Parkinson&#x2019;s Model Shows Nitrosative Stress-Induced Dysfunction in MEF2-PGC1&#x3b1; Transcription. Cell. 2013;155:1351&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4028128</ArticleId><ArticleId IdType="pubmed">24290359</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouroupi G., Taoufik E., Vlachos I.S., Tsioras K., Antoniou N., Papastefanaki F., Chroni-Tzartou D., Wrasidlo W., Bohl D., Stellas D., et al. Defective synaptic connectivity and axonal neuropathology in a human iPSC-based model of familial Parkinson&#x2019;s disease. Proc. Natl. Acad. Sci. USA. 2017;114:E3679&#x2013;E3688. doi: 10.1073/pnas.1617259114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1617259114</ArticleId><ArticleId IdType="pmc">PMC5422768</ArticleId><ArticleId IdType="pubmed">28416701</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper O., Seo H., Andrabi S., Guardia-Laguarta C., Graziotto J., Sundberg M., McLean J.R., Carrillo-Reid L., Xie Z., Osborn T., et al. Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson&#x2019;s Disease. Sci. Transl. Med. 2012;4:141ra190. doi: 10.1126/scitranslmed.3003985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003985</ArticleId><ArticleId IdType="pmc">PMC3462009</ArticleId><ArticleId IdType="pubmed">22764206</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke M., Chong C.-M., Zeng H., Huang M., Huang Z., Zhang K., Cen X., Lu J.-H., Yao X., Qin D., et al. Azoramide protects iPSC-derived dopaminergic neurons with PLA2G6 D331Y mutation through restoring ER function and CREB signaling. Cell Death Dis. 2020;11:130. doi: 10.1038/s41419-020-2312-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-2312-8</ArticleId><ArticleId IdType="pmc">PMC7028918</ArticleId><ArticleId IdType="pubmed">32071291</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker B.M., Chen C.S. Deconstructing the third dimension&#x2014;how 3D culture microenvironments alter cellular cues. J. Cell Sci. 2012;125:3015&#x2013;3024. doi: 10.1242/jcs.079509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.079509</ArticleId><ArticleId IdType="pmc">PMC3434846</ArticleId><ArticleId IdType="pubmed">22797912</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolognin S., Foss&#xe9;pr&#xe9; M., Qing X., Jarazo J., &#x160;&#x10d;an&#x10d;ar J., Moreno E.L., Nickels S.L., Wasner K., Ouzren N., Walter J., et al. 3D Cultures of Parkinson&#x2019;s Disease-Specific Dopaminergic Neurons for High Content Phenotyping and Drug Testing. Adv. Sci. 2019;6:1800927. doi: 10.1002/advs.201800927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.201800927</ArticleId><ArticleId IdType="pmc">PMC6325628</ArticleId><ArticleId IdType="pubmed">30643711</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethna F., Moon C., Wang H. From FMRP Function to Potential Therapies for Fragile X Syndrome. Neurochem. Res. 2014;39:1016&#x2013;1031. doi: 10.1007/s11064-013-1229-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-013-1229-3</ArticleId><ArticleId IdType="pmc">PMC4024105</ArticleId><ArticleId IdType="pubmed">24346713</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson C.A., Davenport M.H., Schaefer T.L., Wink L.K., Pedapati E.V., Sweeney J.A., Fitzpatrick S.E., Brown W.T., Budimirovic D., Hagerman R.J., et al. Fragile X targeted pharmacotherapy: Lessons learned and future directions. J. Neurodev. Disord. 2017;9:7. doi: 10.1186/s11689-017-9186-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s11689-017-9186-9</ArticleId><ArticleId IdType="pmc">PMC5467059</ArticleId><ArticleId IdType="pubmed">28616096</ArticleId></ArticleIdList></Reference><Reference><Citation>Alisch R.S., Wang T., Chopra P., Visootsak J., Conneely K.N., Warren S.T. Genome-wide analysis validates aberrant methylation in fragile X syndrome is specific to the FMR1locus. BMC Med. Genet. 2013;14:18. doi: 10.1186/1471-2350-14-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2350-14-18</ArticleId><ArticleId IdType="pmc">PMC3599197</ArticleId><ArticleId IdType="pubmed">23356558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A.W., Ventola P., Budimirovic D., Berry-Kravis E., Visootsak J. Clinical Development of Targeted Fragile X Syndrome Treatments: An Industry Perspective. Brain Sci. 2018;8:214. doi: 10.3390/brainsci8120214.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci8120214</ArticleId><ArticleId IdType="pmc">PMC6315847</ArticleId><ArticleId IdType="pubmed">30563047</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T., Bray S.M., Warren S.T. New perspectives on the biology of fragile X syndrome. Curr. Opin. Genet. Dev. 2012;22:256&#x2013;263. doi: 10.1016/j.gde.2012.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gde.2012.02.002</ArticleId><ArticleId IdType="pmc">PMC3653273</ArticleId><ArticleId IdType="pubmed">22382129</ArticleId></ArticleIdList></Reference><Reference><Citation>Vershkov D., Ben-Hur T., Benvenisty N. Chapter 6&#x2014;Modeling Fragile X Syndrome Using Human Pluripotent Stem Cells. In: Willemsen R., Kooy R.F., editors. Fragile X Syndrome. Academic Press; London, UK: 2017. pp. 103&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-804461-2.00006-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Mor-Shaked H., Eiges R. Modeling Fragile X Syndrome Using Human Pluripotent Stem Cells. Genes. 2016;7:77. doi: 10.3390/genes7100077.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes7100077</ArticleId><ArticleId IdType="pmc">PMC5083916</ArticleId><ArticleId IdType="pubmed">27690107</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Nur O., Caspi I., Benvenisty N. Molecular analysis of FMR1 reactivation in fragile-X induced pluripotent stem cells and their neuronal derivatives. J. Mol. Cell Biol. 2012;4:180&#x2013;183. doi: 10.1093/jmcb/mjs007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jmcb/mjs007</ArticleId><ArticleId IdType="pubmed">22430918</ArticleId></ArticleIdList></Reference><Reference><Citation>Vershkov D., Fainstein N., Suissa S., Golan-Lev T., Ben-Hur T., Benvenisty N. FMR1 Reactivating Treatments in Fragile X iPSC-Derived Neural Progenitors In Vitro and In Vivo. Cell Rep. 2019;26:2531&#x2013;2539.e4. doi: 10.1016/j.celrep.2019.02.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.02.026</ArticleId><ArticleId IdType="pubmed">30840878</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva M.C., Haggarty S.J. Human pluripotent stem cell&#x2013;derived models and drug screening in CNS precision medicine. Ann. N. Y. Acad. Sci. 2020;1471:18&#x2013;56. doi: 10.1111/nyas.14012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.14012</ArticleId><ArticleId IdType="pubmed">30875083</ArticleId></ArticleIdList></Reference><Reference><Citation>Song M., Paul S., Lim H., Dayem A.A., Cho S.-G. Induced pluripotent stem cell research: A revolutionary approach to face the challenges in drug screening. Arch. Pharmacal Res. 2012;35:245&#x2013;260. doi: 10.1007/s12272-012-0205-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12272-012-0205-9</ArticleId><ArticleId IdType="pubmed">22370779</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang N., Trujillo C.A., Negraes P.D., Muotri A.R., Lameu C., Ulrich H. Stem cell contributions to neurological disease modeling and personalized medicine. Prog. Neuro Psychopharmacol. Biol. Psychiatry. 2018;80:54&#x2013;62. doi: 10.1016/j.pnpbp.2017.05.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2017.05.025</ArticleId><ArticleId IdType="pubmed">28576415</ArticleId></ArticleIdList></Reference><Reference><Citation>Little D., Ketteler R., Gissen P., Devine M.J. Using stem cell&#x2013;derived neurons in drug screening for neurological diseases. Neurobiol. Aging. 2019;78:130&#x2013;141. doi: 10.1016/j.neurobiolaging.2019.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.02.008</ArticleId><ArticleId IdType="pubmed">30925301</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>